Ethocel

ETHOCEL™ (Ethylcellulose): A Comprehensive Reference Article

1. Identity, Nomenclature, and Natural Origin

ETHOCEL™ is the registered trade name owned by IFF (International Flavors & Fragrances, formerly Dow Chemical Company) for its family of ethylcellulose polymers. The chemical name is ethylcellulose, and the ingredient belongs to the chemical family of Cellulose & Cellulosics / Cellulose Ethers, with a plant-based raw material origin.

Ethylcellulose is a derivative of cellulose in which some of the hydroxyl groups on the repeating glucose units are converted into ethyl ether groups. Cellulose itself is one of the most abundant polymers in nature, produced by photosynthesis and constituting a basic plant component; it is a linear polymer composed of glucopyranose residues connected by 1,4-β-glycosidic bonds.

Ethylcellulose is prepared by treating purified cellulose, sourced from chemical-grade cotton linters and wood pulp, with an alkaline solution, followed by ethylation of the alkali cellulose with chloroethane (ethyl chloride). The raw starting material — cellulose — is therefore of entirely plant origin, making ethylcellulose a semi-synthetic derivative of a natural polymer.

The CAS registry number for ethylcellulose is 9004-57-3. In the European Union food additive system, ethylcellulose carries the designation E 462. According to its intended use, commercially available EC can be classified in two categories: industrial grade and pharmaceutical grade; for the pharmaceutical grade, quality standards must meet USP, Ph. Eur., Chinese Pharmacopoeia, and Japanese Pharmacopoeia standards.

Degree of Substitution and Chemical Structure

EC contains 44–51% ethoxyl groups (–OC₂H₅) and is composed of β-anhydroglucose units joined together via acetal linkage. The degree of substitution (DS) designates the average number of hydroxyl positions on the anhydroglucose unit that have been reacted with ethyl chloride; since each anhydroglucose unit has three hydroxyl groups, the maximum value for DS is three. Water solubility is achieved with a DS between 1.0–1.5, while solubility in organic solvents is achieved with DS values in the range of 2.2–2.6; ethylcellulose commercial products, including ETHOCEL™, usually have DS values ranging between 2.2 and 2.6 per anhydrous glucose unit and are marketed in a number of different viscosity grades.

The USP monograph requirement for ethyl ether content is from 44 to 51%. EC is a biocompatible, non-allergenic, nonirritant, colorless, odorless, and tasteless hydrophobic polymer soluble in a wide variety of organic solvents (alcohols, ketones, and polycyclic aromatic hydrocarbons), but does not dissolve in water, glycerin, or propylene glycol; EC that contains no less than 46.5% of ethoxyl groups is freely soluble in chloroform, ethanol, ethyl acetate, methanol, and toluene.

Physical Characteristics

ETHOCEL ethylcellulose polymers are colorless, odorless, tasteless, and noncaloric. ETHOCEL™ Standard 4 Premium Ethylcellulose is a white powder that is soluble in ethanol and organic solvents. As a water-insoluble film-forming material, ETHOCEL™ polymers are useful for taste masking pharmaceutical active ingredients in addition to forming controlled release coatings for multiparticulates or providing an additional moisture barrier for water-sensitive ingredients; ETHOCEL™ polymers also have excellent thermoplastic properties and are capable of being melt extruded into various forms.

2. History and Commercial Development

The Dow Chemical Company introduced its ETHOCEL™ ethylcellulose resins in 1935, entering the plastics sector and establishing one of the first large-scale operations. Prior to 1936, all ethyl cellulose consumed in the US was imported, but American manufacturers rapidly scaled up to meet growing demand.

Key technological advancements in the early 1940s further refined production efficiency, with a notable patent, US Patent 2,254,249, granted in 1941. Post-World War II, production expanded significantly, driven by demand in sectors such as coatings and pharmaceuticals.

ETHOCEL is a trademark of IFF for its family of thermoplastic cellulose ethers, and these polymers have provided excellent service to industry since their commercial introduction by Dow in the mid-1930s. The ETHOCEL™ trademark passed from Dow Chemical to DuPont following the Dow-DuPont merger, and subsequently to IFF (International Flavors & Fragrances) as part of IFF's acquisition of DuPont's Nutrition & Biosciences division.

This product has an excellent safety record and has been widely used by the pharmaceutical industry for over 50 years.

3. Synthesis and Manufacturing

Ethylcellulose is synthesized through the substitution of the cellulose hydroxyl moieties with ethoxyl groups. Synthesis (etherification) steps involve dissolution of cellulose in sodium hydroxide aqueous solution (50% w/w or greater), leading to the breakdown of the cellulose supramolecular structure, resulting in the formation of an alkali cellulose and exposure of the cellulose hydroxyl group for reaction. Subsequently, ethyl chloride gas is added to the reaction medium, leading to reaction with the alkalized cellulose, yielding ethylcellulose plus two by-products: sodium chloride and water.

The physical characteristics of ethylcellulose polymer types and their performances are primarily dependent on the degree of etherification or substitution (ethoxyl content) and molecular weight of the cellulosic backbone.

ETHOCEL™ ethylcellulose polymers are organosoluble products with a narrow specification and uniform ethoxyl functionality; this enables ETHOCEL™ to have very predictable performance, key to industrial applications where the same output is desired batch to batch.

4. Common Forms, Grades, and Preparations

The ETHOCEL™ product line encompasses multiple viscosity grades. These grades are differentiated primarily by viscosity — measured as the viscosity of a 5% w/w solution in a mixture of 80% toluene and 20% ethanol at 25°C — and include Standard 4, Standard 7FP (fine powder), Standard 10, Standard 10FP, Standard 14, Standard 20, Standard 45, Standard 100, Standard 100FP, and Medium 50 and Medium 70 variants.

Several viscosity grades are offered with high purity, making ETHOCEL™ an excellent option for a variety of unique formulation and processing needs. The fine powder (FP) grades can be compressed to form hydrophobic matrix tablets for oral controlled release with a non-gel forming mechanism.

ETHOCEL™ offers binding, controlled release, flexibility, and thermal stability, and is compatible with various manufacturing processes including direct compression, encapsulation, granulation, hot melt extrusion, and tablet coating.

Beyond the dry resin/powder form, ethylcellulose is also commercially available as an aqueous dispersion under trade names such as Surelease® (Colorcon) and Aquacoat® ECD (FMC BioPolymer). These aqueous dispersions were specifically developed to eliminate the need for organic solvents during film coating operations in pharmaceutical manufacturing.

5. Traditional and Historical Use

Ethylcellulose, as a semi-synthetic polymer derived via industrial etherification chemistry, has no pre-modern traditional use by any culture. Its history is entirely modern and industrial, beginning in the 1930s. There is no documented use of ethylcellulose in Ayurvedic, Traditional Chinese Medicine, indigenous, or European herbal traditions, and claims of such would be anachronistic given that the compound did not exist before twentieth-century synthetic chemistry.

The historically recognized substrate — cellulose from plant cell walls — has, of course, been a dietary component throughout human evolution via dietary fiber in plant foods. However, the chemically modified derivative ethylcellulose is a distinct, manufactured substance with no historical record of deliberate therapeutic or nutritional administration.

The earliest documented industrial applications of ETHOCEL™ (from the mid-1930s onward) were in coatings, lacquers, hot-melt inks, and plastics. Pharmaceutical applications emerged progressively over subsequent decades, as pharmaceutical technologists recognized the polymer's utility as a film-former and controlled-release matrix agent. Post-World War II, production expanded significantly, driven by demand in sectors such as coatings and pharmaceuticals.

6. Key Constituents and Chemical Properties

ETHOCEL™ is a single-entity material rather than a botanical extract containing multiple phytochemical constituents. Its relevant chemical and physicochemical attributes are as follows:

• Polymer backbone: ETHOCEL ethylcellulose polymers are derived from and have the polymeric "backbone" of cellulose, a naturally occurring polymer; the molecule has a structure of repeating anhydroglucose units, where each anhydroglucose unit (ring) has three reactive –OH (hydroxyl) sites.
• Ethoxyl substitution: EC contains 44–51% ethoxyl groups (–OC₂H₅) and is composed of β-anhydroglucose units joined together via acetal linkage.
• Water insolubility: It is insoluble at any pH that occurs in organisms, but it undergoes swelling in the presence of gastric juice.
• Non-caloric character: Ethylcellulose polymers are essentially tasteless, odorless, and non-caloric, making them ideal candidates for pharmaceutical, food, and personal care applications.
• Non-metabolism: They are not metabolized following oral consumption and therefore do not usually add to body calories.
• Plasticizer compatibility: EC is compatible with a wide array of excipients and most of the plasticizers used in pharmaceutical formulations, and therefore can be well mixed with many softeners, oils, and waxes.

7. Mechanisms of Action in Drug and Supplement Delivery

ETHOCEL™ / ethylcellulose does not itself exert pharmacological or nutritional action as a "bioactive" in the conventional sense. Its functional utility arises entirely from its physicochemical properties when used as an excipient or formulation ingredient. The principal mechanisms operating when ethylcellulose is used in oral or topical dosage forms include:

7.1 Diffusion-Controlled Release

Being a water-insoluble polymer, the release of a water-soluble drug from an ethylcellulose matrix is mainly driven by permeation through the hydrophobic membrane of EC within water-filled pores. In vitro release studies of microsphere formulations have revealed the ability of EC microspheres to prolong drug release for a period exceeding 12 hours, with the release kinetic study showing that the mechanism of drug release was diffusion controlled — the drug being released through pores and channels present in the microsphere's matrix.

7.2 Hydrophobic Matrix Tablet Technology

It has been found that with increasing the proportion of ethylcellulose ether derivative in the matrix, drug release was significantly extended up to 24 hours, with tablets exhibiting zero-order or nearly zero-order drug transport mechanism. Matrix-based systems employing ETHOCEL™ fine powder grades function without gel formation, distinguishing them mechanistically from hydrophilic matrix systems based on hydroxypropyl methylcellulose (HPMC).

7.3 Barrier Membrane Coating

Ethylcellulose is one of the most commonly used polymers to develop reservoir-type extended release multiparticulate dosage forms; for multiparticulate extended release dosage forms, the drug release is typically governed by the properties of the barrier membrane coating. Porous phase-separated ethylcellulose/hydroxypropylcellulose (EC/HPC) films are used to control drug transport out of pharmaceutical pellets, applied using fluidized bed spraying; drug transport rate is determined by the structure of the porous films that are formed as the water-soluble HPC leaches out.

7.4 Microencapsulation

EC is used to form water-insoluble films, and since coated films of higher viscosity grade EC are stronger, they are used for drug microencapsulation. This water-insoluble polymer can be used in extended release multiparticulate coating, the micro-encapsulation of actives, taste-masking of bitter actives, as an extended release binder in inert matrix systems, and as a solvent and extrusion granulation aid.

7.5 Taste Masking

As a water-insoluble film-forming material, ETHOCEL™ polymers are useful for taste masking pharmaceutical active ingredients in addition to forming controlled release coatings. By encapsulating bitter or unpleasant-tasting active pharmaceutical ingredients (APIs) or dietary supplement compounds within an EC film, the polymer acts as a physical barrier that prevents contact between the active compound and the taste receptors of the oral mucosa.

7.6 Moisture Barrier

ETHOCEL™ polymers can provide an additional moisture barrier for water-sensitive ingredients. This function is particularly relevant for dietary supplements containing moisture-sensitive active compounds such as certain vitamins, enzymes, or probiotics.

7.7 Viscosity-Dependent Performance

In sustained-release metformin hydrochloride nanoparticulate systems, the effect of different viscosity EC grades on in vitro characteristics was investigated; the sustainability of EC was enhanced by the increase in its apparent viscosity — EC with higher viscosity grade sustained metformin release more efficiently. The ethylcellulose 10- and 20-cP grades offer the most robust performance with reduced processing time, and viscosity variation within these grades did not contribute a significant variation in the drug release profile.

8. Applications and Areas of Use in Dietary Supplements and Pharmaceuticals

EC has been widely used in the pharmaceutical industry for decades, being utilized in oral and topical pharmaceutical formulations for various purposes. Ethylcellulose is used in pharmaceutical technology as a coating agent, flavoring fixative, binder, filler, film-former, drug carrier, or stabilizer.

8.1 Oral Controlled/Extended Release Tablets and Capsules

The predominant application of ETHOCEL™ in the dietary supplement and pharmaceutical sectors is as a rate-controlling matrix former or membrane coating in oral solid dosage forms designed for extended or sustained drug/nutrient release. The efficiency of a matrix-forming polymer in sustaining drug release is a multiple function of the physicochemical nature of the active ingredient and the pH of the surrounding environment; matrix tablets of diclofenac sodium, theophylline, and diltiazem HCl have been prepared using ethylcellulose as the matrix-forming agent and studied over 10 hours in buffer media of pH 1.2, 4.5, and 6.8.

Controlled-release matrix tablets of ciprofloxacin have been prepared at different drug-to-polymer (D:P) ratios by direct compression using a fine particle-sized ethylcellulose ether derivative (ETHOCEL Standard Premium 7FP) as the rate-controlling polymer.

8.2 Multiparticulate Pellet and Bead Coatings

Acetaminophen-coated multiparticulates exhibited slower drug release and longer lag time when compared to equivalent metoprolol tartrate multiparticulates; based on such studies, all grades of ethylcellulose are suitable for organic solvent coating of extended release barrier membrane multiparticulates.

8.3 Microspheres

Microspheres have been prepared with varying concentrations of a mixture of two polymers — a water-insoluble polymer, ethylcellulose (EC), and a water-soluble polymer, polyethylene glycol-6000 (PEG-6000) — to retard the release rate of drugs. In optimized formulations, a drug-to-polymer ratio of 1:3 w/w produced microspheres with particle size in the range 600–1000 μm, with 87.6% yield and 80.14 ± 0.53% encapsulation efficiency; drug release from the microspheres was found to be diffusion controlled, with pH-independent behavior.

8.4 Topical and Transdermal Applications

Ethylcellulose polymers are generally employed in oral and topical pharmaceutical formulation as well as food products. In topical formulations, EC functions as a film former, thickener, and matrix former in patches, gels, and creams. EC, due to its poor solubility in water, is often utilized as a backing material in buccal and oral mucosal films.

8.5 Buccal and Oral Film Delivery

Mucoadhesive films can firmly adhere to the buccal mucosa for an extended period, prolonging drug release time and enhancing bioavailability; cellulose ethers have been used in the preparation of buccal films to control drug release by improving bioavailability and reducing side effects.

8.6 Food and Nutraceutical Applications

Ethylcellulose is authorized, quantum satis, for use as a food additive in the EU in accordance with Annex II to Regulation (EC) No 1333/2008; as a food additive, it is used as a stabilizer, thickener, and as a coating agent for microencapsulation, and it is also widely used in the pharmaceutical industry for this purpose.

Food-grade ethyl cellulose is a non-toxic film and thickener which is not water soluble. In the nutraceutical and functional food sectors, EC is used to microencapsulate sensitive bioactives such as omega-3 fatty acids, carotenoids, and probiotics, protecting them from oxidation, moisture, and gastrointestinal degradation prior to release at the intended site.

8.7 Hot Melt Extrusion

Ethylcellulose polymers have found use as matrix formers and release extenders in oral tablet formulations; 3D-printed tablets of ibuprofen with internal scaffolding structure elicited sustained release characteristics associated with the inclusion of ethylcellulose Standard 10, which was first fused and then extruded in filaments with other excipients by hot melt extrusion, and the resulting filaments were printed into extended release tablets by fused deposition modelling.

9. Scientific Evidence by Area of Use

It is critically important to note that ETHOCEL™ / ethylcellulose is an excipient and delivery vehicle, not a bioactive compound. Therefore, there are no controlled human clinical trials evaluating ethylcellulose itself as a pharmacologically or nutritionally active ingredient. The scientific literature on ethylcellulose is voluminous, but it pertains overwhelmingly to its performance as a formulation tool — specifically, its ability to reliably control the release of other active compounds.

9.1 In Vitro Drug Release Studies

The body of in vitro evidence is extensive and well characterized. In microcapsule studies, drug release has been shown to be controlled by the diffusion of drug through the pores and not through the swollen polymer; from Korsmeyer-Peppas modeling, the mode of release from microcapsules was found to be anomalous (non-Fickian), representing a combination of diffusion and erosion mechanisms. These in vitro findings are reproducible across multiple drug types and viscosity grades.

9.2 In Vivo Preclinical Studies

In vivo drug release performance of developed controlled release formulations using EC has been investigated. Animal pharmacokinetic studies have generally confirmed that EC matrix tablets achieve sustained plasma drug concentrations consistent with the extended release profiles observed in vitro, supporting biorelevance of the in vitro models. However, these are formulation studies of the drugs carried by EC — not studies of EC itself as a therapeutic agent.

9.3 Human Clinical Evidence

There are no published randomized controlled trials (RCTs) or systematic reviews evaluating the health effects of orally consumed ETHOCEL™ / ethylcellulose per se in human subjects. Its safety in humans has been inferred from its physicochemical inertness, long-term use in approved pharmaceutical products, regulatory GRAS status, and the absence of reported adverse events, rather than from dedicated clinical efficacy trials. Non-clinical and clinical studies of ethylcellulose as a standalone material are limited; however, it is reasonable to assume this excipient will behave similarly to other modified cellulose products, and due to the lack of bioavailability, the primary effects of these molecules are limited to the GI tract.

9.4 Colon-Targeted Delivery (Preclinical)

An investigation employed ethylcellulose together with pectin as a coating for oral minispheres that regulated ciclosporin release kinetics within the small intestine, enhanced delivery and uptake in the colon of the porcine model employed, indicating improved clinical advantages in the treatment of inflammatory conditions of the large intestines. This is preclinical (animal) evidence only.

9.5 Evidence Strength Summary

The overall evidentiary picture is as follows:

• In vitro / formulation science: Extensive, well-replicated, and high quality for the intended function of controlled release.
• Preclinical (animal) pharmacokinetics: Supportive of in vitro-to-in vivo correlation for formulated drug products.
• Human clinical trials for EC as bioactive: None identified. Not applicable, as ethylcellulose is not a bioactive ingredient.
• Safety evidence in humans: Substantial, arising from decades of regulatory approvals and use in approved pharmaceutical products globally.

10. Body Systems Associated with ETHOCEL™ Use

As a delivery excipient, ETHOCEL™ facilitates the controlled release of active ingredients targeting the following body systems and health areas, depending on the active pharmaceutical ingredient or nutraceutical it encapsulates or coats:

• Gastrointestinal tract: As the primary site of oral drug absorption and as the target organ for colon-specific delivery systems.
• Cardiovascular system: Via extended-release formulations of cardiovascular drugs (e.g., metoprolol tartrate) where EC is the rate-controlling polymer.
• Central nervous system: Via extended-release formulations of CNS drugs (e.g., pregabalin).
• Musculoskeletal / anti-inflammatory: Via coatings for anti-inflammatory drugs such as diclofenac sodium and ibuprofen.
• Nutritional / nutraceutical: Protection and controlled delivery of sensitive dietary supplement actives including vitamins, omega-3 fatty acids, and probiotics.

Ethylcellulose polymers have demonstrated the potential to modulate and improve the physiological performance of bioactives, leading to desired enhanced prophylactic and therapeutic outcomes — but this statement applies to the active compounds they deliver, not to ethylcellulose itself.

11. Dosage Forms and Dosage Levels Reported in Studies

Ethylcellulose is used at varying levels depending on the dosage form and target release profile. The following dosage parameters have been reported in the peer-reviewed literature:

• Matrix tablets (direct compression): Controlled-release matrix tablets of ciprofloxacin have been prepared at different drug-to-polymer (D:P) ratios by direct compression using ETHOCEL Standard Premium 7FP as the rate-controlling polymer.
• Microspheres (pregabalin): The optimum formulation was prepared at a drug-to-polymer ratio of 1:3 w/w, stirring speed of 600 rpm, surfactant concentration of 1.5%, and external phase volume of 150 mL.
• Metoprolol tartrate microspheres: Complete release of metoprolol tartrate occurred from certain formulations in phosphate buffer solution (pH 7.4) within 7–8 hours, while nearly complete release (98.5%) of metoprolol occurred from one formulation in 10 hours.
• Aqueous coating weight gain: Tablets were coated to 2%–8% w/w weight gain in a fully perforated coating pan, with standard coating processing parameters including product temperature 42°C–45°C, spray rate of 6–8 g/min, and air flow of 290 m³/h.
• Pore former content effect: Increasing the pore former content from 15% to 40% w/w within the ethylcellulose coating resulted in elimination of lag time followed by first-order drug release kinetics.

No specific dosage of ethylcellulose as a consumed supplement ingredient for human health benefit has been reported in authoritative sources, consistent with its identity as an inert excipient rather than a pharmacologically active compound.

12. Regulatory Status

Premium ethylcellulose polymers are classified as United States Food and Drug Administration Generally-Recognized-As-Safe (GRAS) chemical substances and have been extensively utilized within the biomedical and pharmaceutical industries for over half a century.

Ethylcellulose is generally regarded as safe (GRAS) and included in the US Food and Drug Administration (FDA) Inactive Ingredients database as well as in the Canadian List of Acceptable Non-medicinal Ingredients to be utilized in oral capsules, suspensions, tablets, topical emulsions, and vaginal or ocular preparations.

The FDA previously granted GRAS status to ethylcellulose as a substance migrating to food from paper and paperboard products (21 CFR 182.90).

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) assessed the compound together with six other cellulose derivatives and allocated a group Acceptable Daily Intake (ADI) of "not specified"; the Scientific Committee for Food (SCF), which assessed five closely related cellulose derivatives, also allocated a group ADI of "not specified."

A specific opinion on ethyl cellulose when used as a food additive was produced by the EFSA Panel on Flavourings, Processing Aids and Materials in Contact with Food (AFC) in 2004, in which the group ADI "not specified" was retained; the most recent evaluation of cellulose and cellulose derivatives, including ethyl cellulose, for their use as food additives was conducted in 2018 by the EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), which concluded that there was no need to set a numerical ADI.

Ethyl cellulose (E 462) is currently authorised as a feed additive for all animal species, without a minimum and a maximum content.

For the pharmaceutical grade, quality standards should meet USP, Ph. Eur., Chinese Pharmacopoeia, and Japanese Pharmacopoeia standards.

13. Safety Considerations and Notable Interactions

13.1 General Safety Profile

There is very limited data detailing possible side effects of EC, hence it is generally regarded as safe (GRAS). Ethylcellulose polymers are normally viewed as non-toxic, non-irritating, and non-allergenic.

They are not metabolized following oral consumption and therefore do not usually add to body calories. The polymer is accepted for use as a food additive because it is a non-calorific and metabolically inert substance following oral consumption.

13.2 WHO and JECFA Position on ADI

As EC is not considered to be a health hazard, the World Health Organisation (WHO) has not specified its acceptable daily intake. The JECFA group ADI designation of "not specified" reflects the highest safety classification assigned by these international expert bodies.

13.3 Gastrointestinal Effects

While the potential for GI effects (e.g., laxative effects) must be considered, the available data suggest minimal risk associated with oral administration of high doses of ethylcellulose. Due to the lack of bioavailability, the primary effects of these molecules are limited to the GI tract.

13.4 Parenteral Use — Renal Consideration

Ethylcellulose polymers are often not recommended for use as excipients in parenteral products because they are not metabolized in the body and may be harmful to the kidneys. This consideration applies specifically and exclusively to intravenous or injectable routes of administration; it is not relevant to oral or topical use.

13.5 pH Insolubility and GI Tract Behavior

In contrast to other polymers which are insoluble in the gastrointestinal tract (e.g., nitrocellulose, cellulose acetate, Eudragit RL, or Eudragit RS), EC is characterized as a non-ionic polymer. It is insoluble at any pH that occurs in organisms, but it undergoes swelling in the presence of gastric juice. This swelling without dissolution means EC matrix tablets may remain as intact, swollen structures and pass into the stool — a recognized and well-documented phenomenon with insoluble matrix formulations that does not indicate treatment failure or harm.

13.6 EFSA Feed Safety Assessment

Based on data provided to EFSA, the feed additive ethyl cellulose was properly identified and characterised and was shown to meet the specifications set for the food additive; the feed additive is considered safe for all animal species, the consumer, and the environment.

13.7 Drug Interactions

Because ethylcellulose is not absorbed, does not undergo hepatic metabolism, and does not interact with CYP450 enzymes or drug transporters, no pharmacokinetic drug-drug interactions involving ethylcellulose itself have been identified in the literature. The interaction profile of any specific EC-coated or EC-matrix formulation is determined entirely by the active ingredient it contains, not by the EC itself. The rate of release of the active ingredient can be modulated by co-ingestion of food (particularly high-fat meals), changes in gastrointestinal motility, and in some formulations, by the co-presence of pore-forming polymers — but these are formulation-level considerations rather than intrinsic properties of ethylcellulose as a material.

13.8 Chronic Exposure Data

Chronic toxicity studies have been performed with several cellulose derivatives; although there were some inconsistencies in the data, the main effects seen were decreases in body weight gain at the highest dose, which are likely due to the amount/bulk of celluloses in the diet leading to nutritional imbalance. The no observed adverse effect level (NOAEL) values reported for cellulose derivatives ranged up to 9,000 mg/kg bw per day.

References

• Wasilewska K, Winnicka K. Ethylcellulose–A Pharmaceutical Excipient with Multidirectional Application in Drug Dosage Forms Development. Materials (Basel). 2019;12(20):3386. PMC6829386.
• Arca HC, Mosquera-Giraldo LI, Bi V, Xu D, Taylor LS, Edgar KJ. Premium ethylcellulose polymer based architectures at work in drug delivery. Carbohydr Polym. 2019. PMC6733301.
• Shah KU, Khan GM. Regulating Drug Release Behavior and Kinetics from Matrix Tablets Based on Fine Particle-Sized Ethyl Cellulose Ether Derivatives: An In Vitro and In Vivo Evaluation. ISRN Pharm. 2012. PMC3350987.
• Badawi AA, et al. Formulation and evaluation of controlled release ethylcellulose and polyethylene glycol microspheres containing metoprolol tartrate. Int J Pharm Investig. 2016. PMC5370352.
• Murtaza G, et al. Release behavior of different physicochemical properties drug models from the ethylcellulose microcapsules. Acta Pol Pharm. 2011. PMC3147104.
• Karabas HA, et al. Application of Ethylcellulose Coating to Hydrophilic Matrices: A Strategy to Modulate Drug Release Profile and Reduce Drug Release Variability. AAPS PharmSciTech. 2014. PMC4179654.
• Elkhoudary MM, et al. Preparation and characterization of ethylcellulose microspheres for sustained-release of pregabalin. Drug Dev Ind Pharm. 2021. PMC8074809.
• EFSA FEEDAP Panel. Safety of a feed additive consisting of ethyl cellulose for all animal species (Association Management & Regulatory Services Ltd). EFSA Journal. 2024. PMC10902761.
• EFSA FEEDAP Panel. Safety and efficacy of ethyl cellulose for all animal species. EFSA Journal. 2020;18(7):e06210. PMC7393631.
• EFSA ANS Panel. Re-evaluation of celluloses E 460(i), E 460(ii), E 461, E 462, E 463, E 464, E 465, E 466, E 468 and E 469 as food additives. EFSA Journal. 2018;16(1):5047.
• US FDA. Pharmacological Review — Ethylcellulose (NDA 022577). FDA Center for Drug Evaluation and Research, 2012.
• Murtaza G. Evaluation of ethylcellulose as matrices for controlled release drug delivery. Acta Pol Pharm. 2006;63(1):67-71. PubMed PMID: 16431395.
• Bhattacharya S, et al. Investigation into the Effect of Ethylcellulose Viscosity Variation on the Drug Release of Metoprolol Tartrate and Acetaminophen Extended Release Multiparticulates. AAPS PharmSciTech. 2016;17(1):82-93.
• IFF Pharma Solutions. ETHOCEL™ Premium Ethylcellulose Resins — Product Overview. IFF Pharma Solutions.
• Roquette / Industrial Cellulosics. ETHOCEL™ — Industrial Cellulosics Product Page.
• Hulgren O, et al. Cross-sectional structure evolution of phase-separated spin-coated ethylcellulose/hydroxypropylcellulose films during solvent quenching. J Colloid Interface Sci. 2022. PMC9477114.
• Zhao Y, et al. Characteristics, preparation and applicability in oral delivery systems of cellulose ether-based buccal films. Drug Deliv. 2025. PMC12258245.
• Xu X, et al. Electrosprayed Stearic-Acid-Coated Ethylcellulose Microparticles for an Improved Sustained Release of Anticancer Drug. Pharmaceutics. 2023. PMC10528259.